Currently, for patients with advanced or unresectable HCC, combination therapy with the anti-programmed cell death-ligand 1 (anti-PD-L1) agent atezolizumab and the anti-vascular endothelial growth factor (anti-VEGF) A agent bevacizumab has shown superior progression-free and overall survival compared to sorafenib and is now considered the standard systemic therapy in this setting [5]. This evidence concerns the gene CD274 and hepatocellular carcinoma.